Literature DB >> 8050449

European Study Group on Antibiotic Breakpoints. Breakpoint determination: sparfloxacin.

I Phillips, J Acar, F Baquero, T Bergan, J Degener, A Forsgren, G C Schito, B Wiedemann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8050449     DOI： 10.1007/bf01974556

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  3 in total

1.  Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci.

Authors:  A Ferrara; C Dos Santos; M Cimbro; G Gialdroni Grassi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

2.  Bactericidal effect of sparfloxacin alone and in combination with amoxicillin against Streptococcus pneumoniae as determined by kill-kinetic studies.

Authors:  V Barakett; D Lesage; F Delisle; G Richard; J C Petit
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 3.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.